Wire · opportunities
FDA Clears PrecivityAD2 Blood Test for Alzheimer's in Adults as Young as 40
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 21 August 2026 · Fusion42 review
The FDA cleared C2N Diagnostics' PrecivityAD2 blood test for Alzheimer's detection in symptomatic adults as young as 40, lowering the approved age for clinical use and enabling earlier diagnosis via a scalable blood test. This expands the pool of trial-eligible participants for Alzheimer's studies and signals a shift in trial design and recruitment practices toward younger populations.
This Wire brief sits within Fusion42's coverage of Digital Health, and 13 sources have reported it between 20 Aug 2026 and 26 Sep 2026.
◆ ◆ The Wire takeaway
Alzheimer's drug developers have a new patient group to recruit from immediately, with younger symptomatic adults now diagnosable via blood tests. You should engage trial sites to update protocols and tap this expanded biomarker-confirmed population before competitors do.
◆ Coverage
13 sources · first reported 20 Aug 2026 · latest 26 Sep 2026
◆ Related on Wire
◆ Topics